Roivant Sciences Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
721
- Stock Symbol
-
ROIV
- Investments
-
33
- Share Price
-
$39.53
- (As of Friday Closing)
Roivant Sciences General Information
Description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Contact Information
Website
www.roivant.comCorporate Office
- 1 Pennsylvania Plaza
- 54th Floor
- New York, NY 10119
- United States
Corporate Office
- 1 Pennsylvania Plaza
- 54th Floor
- New York, NY 10119
- United States
Roivant Sciences Stock Performance
As of 13-Nov-2026, Roivant Sciences’s stock price is $39.53. Its current market cap is $28.6B with 725M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $39.53 | $39.99 | $19.96 - $42.50 | $28.6B | 725M | 8.06M | -$0.48 |
Roivant Sciences Financials Summary
As of 30-Sep-2026, Roivant Sciences has a trailing 12-month revenue of $41.1M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 23,371,019 | 16,108,851 | 2,500,018 | 2,824,205 |
| Revenue | 41,082 | 8,260 | 29,053 | 32,713 |
| EBITDA | (457,628) | (439,339) | (925,894) | 4,443,467 |
| Net Income | (344,353) | (299,771) | (171,981) | 4,348,926 |
| Total Assets | 4,975,824 | 5,708,687 | 5,436,940 | 7,222,482 |
| Total Debt | 0 | 107,438 | 100,170 | 53,986 |
Roivant Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Roivant Sciences Comparisons
Industry
Financing
Details
Roivant Sciences Competitors (66)
One of Roivant Sciences’s 66 competitors is Citius Pharma, a Formerly Angel backed company based in Cranford, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Citius Pharma | Formerly Angel backed | Cranford, NJ | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| Denovo Biopharma | Venture Capital-Backed | Hangzhou, China | ||||
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Roivant Sciences Patents
Roivant Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220088158-A1 | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase | Inactive | 23-Jan-2019 | ||
| US-11266652-B2 | Methods of treating subjects having diabetes with chronic kidney disease | Active | 06-Jun-2018 | ||
| US-12036226-B2 | Methods of treating subjects having diabetes with chronic kidney disease | Active | 06-Jun-2018 | ||
| US-20200215072-A1 | Methods of treating subjects having diabetes with chronic kidney disease | Active | 06-Jun-2018 | ||
| US-20220387437-A1 | Methods of treating subjects having diabetes with chronic kidney disease | Active | 06-Jun-2018 | A61K31/53 |
Roivant Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Roivant Sciences Investments & Acquisitions (33)
Roivant Sciences’s most recent deal was a Seed Round with Proxima (Drug Discovery) for . The deal was made on 09-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Proxima (Drug Discovery) | 09-Jun-2026 | Seed Round | Drug Discovery | ||
| PsiThera | 10-Dec-2025 | Early Stage VC | Drug Discovery | ||
| Zest Health | 03-Feb-2025 | Seed Round | Clinics/Outpatient Services | ||
| Immunovant | 02-Oct-2023 | PIPE | Drug Discovery | ||
| Lokavant | 07-Dec-2022 | Early Stage VC | Laboratory Services (Healthcare) |
Roivant Sciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.9 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Roivant Sciences Exits (14)
Roivant Sciences’s most recent exit was on 07-Dec-2022 from Lokavant. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Lokavant | 07-Dec-2022 | Completed |
|
||
| Telavant | 01-Dec-2022 | Completed |
|
||
| Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) | 01-Nov-2022 | Completed |
|
||
| Datavant | 28-Jul-2021 | Completed |
|
||
| SK Life Science Labs | 06-Dec-2020 | Merger/Acquisition | Completed |
|
Roivant Sciences Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Izana Bioscience | Oxford, United Kingdom | 2017 | |
| Roivant Sciences (Stomach Disease Treatment Drug RVT-3101) |
Roivant Sciences FAQs
-
When was Roivant Sciences founded?
Roivant Sciences was founded in 2014.
-
Where is Roivant Sciences headquartered?
Roivant Sciences is headquartered in New York, NY.
-
What is the size of Roivant Sciences?
Roivant Sciences has 721 total employees.
-
What industry is Roivant Sciences in?
Roivant Sciences’s primary industry is Drug Discovery.
-
Is Roivant Sciences a private or public company?
Roivant Sciences is a Public company.
-
What is Roivant Sciences’s stock symbol?
The ticker symbol for Roivant Sciences is ROIV.
-
What is the current stock price of Roivant Sciences?
As of 13-Nov-2026 the stock price of Roivant Sciences is $39.53.
-
What is the current market cap of Roivant Sciences?
The current market capitalization of Roivant Sciences is $28.6B.
-
What is Roivant Sciences’s current revenue?
The trailing twelve month revenue for Roivant Sciences is $41.1M.
-
Who are Roivant Sciences’s competitors?
Citius Pharma, Genentech, Moderna, Denovo Biopharma, and Crinetics Pharmaceuticals are some of the 66 competitors of Roivant Sciences.
-
What is Roivant Sciences’s annual earnings per share (EPS)?
Roivant Sciences’s EPS for 12 months was -$0.48.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
